| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| F Samuel van Nierop, Emma C E Meessen, Kyra G M Nelissen, Roos Achterbergh, Laureen A Lammers, Frédéric M Vaz, Ron A A Mathôt, Heinz-Josef Klümpen, Steven W Olde Damink, Frank G Schaap, Johannes A Romijn, E Marleen Kemper, Maarten R Soeter. Differential effects of a 40-hour fast and bile acid supplementation on human GLP-1 and FGF19 responses. American journal of physiology. Endocrinology and metabolism. vol 317. issue 3. 2020-03-23. PMID:31237451. |
in this study, we investigated the postprandial bile acid response in plasma and its relation to insulin, glp-1, and fgf19. |
2020-03-23 |
2023-08-13 |
human |
| Hiroki Okauchi, Chiaki Hashimoto, Reiko Nakao, Katsutaka Oish. Timing of food intake is more potent than habitual voluntary exercise to prevent diet-induced obesity in mice. Chronobiology international. vol 36. issue 1. 2020-03-16. PMID:30212233. |
abbreviations: anova: analysis of variance; df: daytime feeding; ffa: free fatty acid; glp-1: glucagon-like peptide-1; homa-ir: homeostasis model assessment of insulin resistance; neat: non-exercise activity thermogenesis; nf: nighttime feeding; rf: restricted feeding; rw: running-wheel; scn: suprachiasmatic nucleus; se: standard error of the mean; sed: sedentary; spa: spontaneous physical activity; t-cho: total cholesterol; tg: triglyceride; wat: white adipose tissues. |
2020-03-16 |
2023-08-13 |
mouse |
| Seyed Ebrahim Alavi, Peter J Cabot, Peter M Moyl. Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency. Molecular pharmaceutics. vol 16. issue 6. 2020-03-16. PMID:31050435. |
glp-1 is a therapeutic peptide secreted from the intestines following food intake, which stimulates the secretion of insulin from the pancreas. |
2020-03-16 |
2023-08-13 |
Not clear |
| Michael A Nauck, Juris J Meie. MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes? European journal of endocrinology. vol 181. issue 6. 2020-03-16. PMID:31600725. |
glp-1, a peptide hormone secreted from the gut, stimulating insulin and suppressing glucagon secretion was identified as a parent compound for novel treatments of diabetes, but was degraded (dipeptidyl peptidase-4) and eliminated (mainly by kidneys) too fast (half-life 1-2 min) to be useful as a therapeutic agent. |
2020-03-16 |
2023-08-13 |
Not clear |
| Shuvasree Sarkar, Chayan Munshi, Sarmishtha Chatterjee, Sandip Mukherjee, Shelley Bhattachary. Vector-free in vivo trans-determination of adult hepatic stem cells to insulin-producing cells. Molecular biology reports. vol 46. issue 5. 2020-03-09. PMID:31102150. |
hepatic stem cells were redirected in vivo to functional insulin producing cells in a acetylaminofluorene-partial hepatectomy (aaf/ph) adult male rat model with/without glp-1 treatment. |
2020-03-09 |
2023-08-13 |
rat |
| Shuvasree Sarkar, Chayan Munshi, Sarmishtha Chatterjee, Sandip Mukherjee, Shelley Bhattachary. Vector-free in vivo trans-determination of adult hepatic stem cells to insulin-producing cells. Molecular biology reports. vol 46. issue 5. 2020-03-09. PMID:31102150. |
results strongly indicated the key role of glp-1 in the induction of insulin secretion in trans-determined reprogrammed cell in vivo. |
2020-03-09 |
2023-08-13 |
rat |
| Brandon J Gheller, Mary Gheller, Athena Li, Fernando Nunes, Younes Anini, N Theresa Glanville, Nick Bellissimo, Jill Hamilton, G Harvey Anderson, Bohdan L Luhovy. Effect of dairy and nondairy snacks on postprandial blood glucose regulation in 9-14-year-old children. Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme. vol 44. issue 10. 2020-02-28. PMID:30794429. |
blood glucose, insulin, c-peptide, and glucagon-like peptide-1 (glp-1) were measured at 0 min (before the snack), and at 30, 60, 90, and 120 min after snack consumption. |
2020-02-28 |
2023-08-13 |
Not clear |
| Yehuda Handelsman, Marcel H A Muskiet, Graydon S Meneill. Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine. Advances in therapy. vol 37. issue 2. 2020-02-26. PMID:31873867. |
correction to: combining glp-1 receptor agonists and basal insulin in older adults with type 2 diabetes: focus on lixisenatide and insulin glargine. |
2020-02-26 |
2023-08-13 |
Not clear |
| Yehuda Handelsman, Marcel H A Muskiet, Graydon S Meneill. Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine. Advances in therapy. vol 37. issue 2. 2020-02-26. PMID:31873867. |
there are some corrections in the original article, page 11, "/lyxumia" word has to be removed from the section rationale for combination therapy comprising glp-1 ras and basal insulin. |
2020-02-26 |
2023-08-13 |
Not clear |
| Zhi-Bing You, Bin Wang, Eliot L Gardner, Roy A Wis. Cocaine and cocaine expectancy increase growth hormone, ghrelin, GLP-1, IGF-1, adiponectin, and corticosterone while decreasing leptin, insulin, GIP, and prolactin. Pharmacology, biochemistry, and behavior. vol 176. 2020-02-25. PMID:30414405. |
cocaine and cocaine expectancy increase growth hormone, ghrelin, glp-1, igf-1, adiponectin, and corticosterone while decreasing leptin, insulin, gip, and prolactin. |
2020-02-25 |
2023-08-13 |
rat |
| Sine Paasch Schiellerup, Kirsa Skov-Jeppesen, Johanne Agerlin Windeløv, Maria Saur Svane, Jens Juul Holst, Bolette Hartmann, Mette Marie Rosenkild. Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment. Frontiers in endocrinology. vol 10. 2020-02-25. PMID:30863364. |
the responsible hormones appear to include glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1 (glp-1), known as incretin hormones due to their role in regulating glucose homeostasis by enhancing insulin release in response to food intake. |
2020-02-25 |
2023-08-13 |
human |
| Wei Ding, Wen-Guang Chang, Xiao-Ci Guo, Ying Liu, Dan-Dan Xiao, Dan Ding, Jian-Xun Wang, Xue-Juan Zhan. Exenatide Protects Against Cardiac Dysfunction by Attenuating Oxidative Stress in the Diabetic Mouse Heart. Frontiers in endocrinology. vol 10. 2020-02-25. PMID:31024445. |
exenatide, a glucagon-like peptide-1 (glp-1) receptor agonist, is used as an add-on therapy to insulin treatment. |
2020-02-25 |
2023-08-13 |
mouse |
| Jens Juul Hols. From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy. Frontiers in endocrinology. vol 10. 2020-02-25. PMID:31080438. |
but resection experiments clearly indicated the presence of an additional incretin, and in 1986, an unexpected processing fragment of the recently identified glucagon precursor, proglucagon, namely truncated glucagon-like peptide 1 (glp-1 7-36 amide), was isolated from the gut and found to both stimulate insulin secretion and inhibit glucagon secretion. |
2020-02-25 |
2023-08-13 |
Not clear |
| Baptist Gallwit. Clinical Use of DPP-4 Inhibitors. Frontiers in endocrinology. vol 10. 2020-02-25. PMID:31275246. |
they stimulate insulin secretion and inhibit glucagon secretion by elevating endogenous glp-1 concentrations without an intrinsic hypoglycaemia risk. |
2020-02-25 |
2023-08-13 |
Not clear |
| Maj Bangshaab, Alejandro Gutierrez, Khiem Dinh Huynh, Jakob Schöllhammer Knudsen, Daniel Dias Rufino Arcanjo, Asbjørn G Petersen, Jørgen Rungby, Michael Gejl, Ulf Simonse. Different mechanisms involved in liraglutide and glucagon-like peptide-1 vasodilatation in rat mesenteric small arteries. British journal of pharmacology. vol 176. issue 3. 2020-02-24. PMID:30403290. |
glucagon-like peptide-1 (glp-1) is an incretin hormone that regulates insulin biosynthesis and secretion in a glucose-dependent manner and has been reported to induce vasodilatation. |
2020-02-24 |
2023-08-13 |
rat |
| Anastasia-Stefania Alexopoulos, John B Bus. Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin. Metabolism: clinical and experimental. vol 98. 2020-02-19. PMID:31255662. |
the basis for this recommendation is the similar glycemic efficacy of glp-1 ras and insulin, but with glp-1 ras promoting weight loss instead of weight gain, at lower hypoglycemia risk, and with cardiovascular benefits in patients with pre-existing cardiovascular disease. |
2020-02-19 |
2023-08-13 |
Not clear |
| Anastasia-Stefania Alexopoulos, John B Bus. Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin. Metabolism: clinical and experimental. vol 98. 2020-02-19. PMID:31255662. |
however, tolerability and costs are important considerations, and notably, rates of drug discontinuation are often higher for glp-1 ras than basal insulin. |
2020-02-19 |
2023-08-13 |
Not clear |
| Anastasia-Stefania Alexopoulos, John B Bus. Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin. Metabolism: clinical and experimental. vol 98. 2020-02-19. PMID:31255662. |
overall healthcare costs may be lower with glp-1 ras compared to insulin. |
2020-02-19 |
2023-08-13 |
Not clear |
| Anastasia-Stefania Alexopoulos, John B Bus. Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin. Metabolism: clinical and experimental. vol 98. 2020-02-19. PMID:31255662. |
though patient-level costs may still be prohibitive, glp-1 ras can replace 50-80 units of insulin daily and reduce costs associated with glucose self-monitoring. |
2020-02-19 |
2023-08-13 |
Not clear |
| Charles Thivolet, Lucien Marchand, Karim Chik. Inappropriate glucagon and GLP-1 secretion in individuals with long-standing type 1 diabetes: effects of residual C-peptide. Diabetologia. vol 62. issue 4. 2020-02-18. PMID:30612138. |
this study aimed to evaluate whether insulin microsecretion could modulate glucagon and glucagon-like peptide-1 (glp-1) responses to a mixed meal tolerance test (mmtt). |
2020-02-18 |
2023-08-13 |
Not clear |